They are given by infusion, require confirmed amyloid on a scan or spinal fluid test, and require regular MRI monitoring for brain swelling and small bleeds, which are the main risks.
They are for early disease only, the benefit is a slowing rather than a reversal, and access depends on insurance and proximity to an infusion centre.
Why it matters
This is the first class of drug shown to affect the disease rather than the symptoms, and it is also demanding, risky for some, and not for everyone.
Sources
Where to check this, and where to read more. All external and all authoritative.